aMBR Genomics, Inc. — SEC Form D Filing

aMBR Genomics, Inc. filed an SEC Form D on March 31, 2026, reporting $1.10M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
March 31, 2026
Amount reported
$1.10M
Round stage
Seed
Industry
Health Care
Website
https://www.ambrgenomics.com/

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Cancer detection methods are often invasive and may not provide early warning. Existing solutions can fail to identify cancers at early stages.

Solution

aMBR Genomics develops non-invasive liquid biopsy techniques using midbody remnants to detect multiple types of cancer early and accurately.

Why now

There is an urgent need for effective early cancer detection solutions, especially non-invasive methods, to improve patient outcomes.

Verdict

Investors said yes to aMBR Genomics at this moment because the urgency for non-invasive cancer detection methods was clear, not because existing solutions proved effective for early-stage detection. They were implicitly betting on the uniqueness of midbody remnants for early cancer detection that could disrupt traditional invasive methods, while the limited upside lies in a crowded space where established companies have already set high standards for efficacy and reliability.

Source: SEC EDGAR Form D filing